Rezolute, Inc. has announced that it will present participant baseline data from its fully enrolled Phase 3 study of Ersodetug, aimed at treating hypoglycemia due to congenital hyperinsulinism, at the upcoming ENDO 2025 Annual Meeting of the Endocrine Society. The abstract, titled "Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress," has been selected for a late-breaking presentation. The presentation will take place on July 14, 2025, in San Francisco, California, during the Pediatric and Adolescent Endocrinology session. The company has completed enrollment for the study and expects to share topline data in December 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.